Palatin Technologies

Update in progress

PTN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Palatin Technologies, Inc. is a biopharmaceutical company developing first‑in‑class medicines that modulate the melanocortin receptor system in the United States. Its programs include PL7737, an oral MC4R agonist in preclinical development; long‑acting MC4R peptides; Bremelanotide with Tirzepatide for obesity in Phase 2; and Bremelanotide with a PDE5 inhibitor for ED in select patients. It also develops PL9643 for dry eye and PL8177 for inflammatory bowel disease. Founded 1986, based in Monmouth Junction, NJ.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive